Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer

NCT ID: NCT02706743

Last Updated: 2016-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to assess the impact of adjuvant radioactive iodine therapy on the quality of life(QOL) in differentiated thyroid cancer patients and to identify independent factors affecting changes in the QOL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thyroid Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologically confirmed new diagnosis of differentiated thyroid cancer, recently treated by total thyroidectomy
* Must sign a consent form before treatment
* One year or more of follow-up after radioiodine ablation

Exclusion Criteria

* Patients with follicular, Hürthle cell, poorly differentiated, medullary, or anaplastic thyroid carcinoma
* Pregnant or lactating women
* Patients that received adjuvant radioiodine treatment in the past
* Patients with other cancer
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Southern Medical University, China

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sun Yungang

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sun Y Gang, Master

Role: PRINCIPAL_INVESTIGATOR

Zhujiang Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhujiang Hospital,Southern Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sun Y Gang, Master

Role: CONTACT

8602062783296 ext. 61643888

OU Y Wei, Master

Role: CONTACT

8613600474406 ext. 61643888

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sun Y Guang, Master

Role: primary

8602062783296 ext. 61643888

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZMing

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.